In Brief: Scios Nova's Auriculin

Executive Summary

Scios Nova's Auriculin: Preliminary results of a Phase III acute renal failure trial show no difference between patients treated with the atrial natriuretic peptide and those who received placebo in the need for dialysis or mortality, the company reports May 3. Scios said the company and its partner Genentech will further evaluate the data but believe that additional clinical studies will be required for an NDA submission. "We will not meet our objective of filing an application in 1995 for marketing approval," the firm says. Results of the trial will be presented at the International Congress of Nephrology in Madrid, Spain in July. Genentech announced in January that it would be investing up to $100 mil. in Scios Nova's Auriculin R&D...